These guidelines were developed by an expert panel composed of health care professionals with expertise in family medicine, general internal medicine, adult and| NHLBI, NIH
The human body is not able to excrete excess amounts of iron actively.[1] Iron is absorbed from the small intestine each day and balanced by losses through sweating, menstruation, shedding of hair and skin cells, and the rapid turnover and excretion of erythrocytes.[2] The average daily absorption and secretion is 1 mg. Patients receiving transfusions for non-iron deficiency anemias are at risk for transfusion-related iron overload. The following is a list of transfusion-dependent conditions:| www.ncbi.nlm.nih.gov
Sickle cell trait is an inherited condition that can be tricky to understand. It is not the same as sickle cell disease, red blood cell disorders that affect hemoglobin, the protein that carries oxygen through the body. In fact, sickle cell trait is not a disease at all. Rather, people with sickle cell trait are born with and carry one gene for sickle cell hemoglobin and one for regular hemoglobin. Learn about what this means for a child who has the condition.| HealthyChildren.org
Before your baby is born, talk to your pediatrician about which screening tests your baby will undergo, including their benefits and any risks, and ask if it is necessary for you to consent to this testing.| HealthyChildren.org
Discuss these questions with your doctor or health care provider.| Genome.gov
Pediatricians have a unique opportunity to discuss health issues such as sickle cell trait with their teenage patients prior to transition to adult care.| www.aap.org
If your child or teen has a blood disease or cancer, a pediatric hematologist/oncologist has the experience and qualifications to evaluate and treat your child or teen.| HealthyChildren.org
Anemia is a condition in which the amount of red blood cells in the body is decreased below normal for your child’s age. It can make your child appear pale in color and feel cranky, tired, or weak.| HealthyChildren.org
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.| U.S. Food and Drug Administration